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OBJECTIVE—To evaluate the direct impact of n-3 polyunsatu-
rated fatty acids (n-3 PUFAs) on the functions and viability of
pancreatic -cells.
RESEARCH DESIGN AND METHODS—We developed an
mfat-1 transgenic mouse model in which endogenous production
of n-3 PUFAs was achieved through overexpressing a C. elegans
n-3 fatty acid desaturase gene, mfat-1. The islets and INS-1 cells
expressing mfat-1 were analyzed for insulin secretion and via-
bility in response to cytokine treatment.
RESULTS—The transgenic islets contained much higher levels
of n-3 PUFAs and lower levels of n-6 PUFAs than the wild type.
Insulin secretion stimulated by glucose, amino acids, and gluca-
gon-like peptide-1 (GLP-1) was signiﬁcantly elevated in the
transgenic islets. When challenged with tumor necrosis factor-
(TNF-), interleukin-1 (IL-1), and -interferon (IFN-), the
transgenic islets completely resisted cytokine-induced cell death.
Adenoviral transduction of mfat-1 gene in wild-type islets and in
INS-1 cells led to acute changes in the cellular levels of n-3- and
n-6 PUFAs and recapitulated the results in the transgenic islets.
The expression of mfat-1 led to decreased production of pros-
taglandin E2 (PGE2), which in turn contributed to the elevation of
insulin secretion. We further found that cytokine-induced activa-
tion of NF-B and extracellular signal–related kinase 1/2
(ERK1/2) was signiﬁcantly attenuated and that the expression of
pancreatic duodenal hemeobox-1 (PDX-1), glucokinase, and in-
sulin-1 was increased as a result of n-3 PUFA production.
CONCLUSIONS—Stable cellular production of n-3 PUFAs via
mfat-1 can enhance insulin secretion and confers strong resis-
tance to cytokine-induced -cell destruction. The utility of
mfat-1 gene in deterring type 1 diabetes should be further
explored in vivo. Diabetes 59:471–478, 2010
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olyunsaturated fatty acids (PUFAs) are synthe-
sized from the modiﬁcation of saturated fatty
acid precursors by different desaturases and
elongation enzymes. Mammals have neither the
desaturase necessary to synthesize the precursors of other
PUFAs, linoleic acid (LA, n-6), and -linolenic acid (ALA,
n-3), nor the n-3 fatty acid desaturase to convert n-6
PUFAs to n-3 PUFAs. Therefore, LA and ALA and their
elongation products are essential fatty acids to mammals
and must be taken from diets (1,2). Physiologically, n-3
PUFAs play critical roles in the development and functions
of retina, spermatozoa, and the central nervous system
(1,3).
A series of epidemiological studies have established the
health beneﬁts of dietary intake of n-3 PUFAs in prevent-
ing cardiovascular diseases and type 2 diabetes (4,5). Two
recent large-scale clinical studies also demonstrated that
long-term dietary intake of ﬁsh oil starting at 1 year of age
lowers the risk of type 1 diabetes and islet autoimmunity
(6,7). Consistent with such epidemiological evidence, re-
cent studies in rodents indicated that dietary gain or direct
administration of n-3 PUFAs could restore palmitate acid–
or linoleic acid–impaired insulin secretion (8,9). An issue
central to this study is whether the effects of n-3 PUFAs on
type 1 diabetes are related to the direct impact on the
functions and viability of -cells. To evaluate such effects
as well as the underlying mechanisms, we developed a
transgenic mouse model that expresses a C. elegans gene,
fat-1, encoding a n-3 fatty acid desaturase (10). Since this
enzyme can convert n-6 PUFAs into the corresponding n-3
forms, transgenic expression of fat-1 will render the host
endogenous capability of producing n-3 PUFAs while
concomitantly reducing the levels of n-6 PUFAs. Using
such a unique animal model, we are able to evaluate the
impact of stable cellular elevation of n-3 PUFAs on insulin
secretion and viability of -cells without the need of
lengthy feeding of ﬁsh oil. The positive outcomes from our
studies may reveal the potential utility of this type of gene
to deter and mitigate type 1 diabetes.
RESEARCH DESIGN AND METHODS
Generation of mfat-1 transgenic mice. The coding region of fat-1 cDNA
was optimized for mammalian cell expression, and the resultant cDNA,
renamed mfat-1, was synthesized by Geneart. The mfat-1 expression cassette,
consisting of the mfat-1 cDNA driven by a cytomegalovirus (CMV) enhancer
and chicken -actin promoter tethered with a muscle creatine kinase (MCK)
enhancer (supplemental Fig. 1, available in an online appendix at http://
diabetes.diabetesjournals.org/cgi/content/full/db09-0284/DC1), was introduc-
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approved by the University of Pittsburgh Institutional Animal Care and Usage
Committee.
Ad-mfat-1 viral vector and infection with adenoviruses. The mfat-1
cDNA was inserted into an adenoviral shuttle vector under the control of CMV
promoter. The generation of Ad-mfat-1 viral vector and the large-scale
preparation of Ad-mfat-1 (and Ad-lacZ) vector were carried out by the Viral
Core Facility at the University of Pittsburgh. Rat insulinoma INS-1 cells
cultured in RPMI-1640 medium were infected in the presence of 7.5 mmol/l
glucose (no serum) with either a control (Ad-lacZ) or Ad-mfat1 virus at a
multiplicity of infection (MOI) of 100 for 4 h. Isolated islets were cultured
overnight after isolation and were then infected for 4 h with Ad-mfat1 or
Ad-lacZ at 250–500 MOI (10
3 cells/islet).
Cytokine treatment and imaging analysis. Adenovirus-infected INS-1 cells
or islets (48 h after) were exposed to the following cytokines: 5 ng/ml human
interleukin-1 (IL-1), 100 ng/ml -interferon (IFN-), and 10 ng/ml tumor
necrosis factor- (TNF-) (Roche Diagnostics) for 48 h. Each experiment was
performed in triplicate. The cells or islets were double stained with propidium
iodide (PI) and Hoescst nuclear dye before imaging analysis using a confocal
microscope for islets or an inverted ﬂuorescent microscope for INS-1 cells.
Islet isolation, glucose-stimulated insulin secretion in islets or INS-1
cells, and quantitative analysis of gene expression levels. Brieﬂy, the
pancreas was injected through the pancreatic duct with Hanks’ buffered saline
solution (HBSS) containing collagenase (type V), excised, incubated in HBSS
for 15 min at 37°C, and then ﬁltered through a 500-m wire mesh. The digested
pancreas was rinsed with HBSS, and islets were separated by Ficoll-gradient
centrifugation. After several washes in HBSS, islets were handpicked under an
inverted light microscope. Insulin release from isolated islets or INS-1 cells
was measured as previous described (11) with some modiﬁcations. INS-1 cells
or groups of 10 islets of similar size were preincubated in Krebs-Ringer
bicarbonate buffer (KRBB) (supplemented with 10 mmol/l HEPES and 0.5%
BSA) and 2.8 mmol/l glucose for1ha t37°C, washed once in KRBB plus 1%
BSA, and then incubated in 1 ml fresh KRBB containing either low glucose (2.8
mmol/l) or high glucose (11.1 for INS-1 or 22.2 mmol/l for islets) for 30 min. In
a parallel set of experiments, the INS-1 cells or the islets were incubated with
KRBB containing high glucose plus 10 nmol/l glucagon-like peptide-1 (GLP-1).
At the end of incubation, supernatant was collected and the cells or islets were
harvested in KRBB for ELISA determination of secreted or cellular insulin
content (Linco Research).
Leucine and glutamine-stimulated insulin secretion in isolated islets.
Groups of 10 islets of similar size were preincubated in KRBB and 1.1 mmol/l
glucose for1ha t37°C, washed once in KRBB, and then incubated in 0.5 ml
fresh KRBB containing 1.1 mmol/l glucose plus 10 mmol/l leucine and 10
mmol/l glutamine for 60 min. At the end of incubation, supernatant was
collected and the islets were harvested in KRBB for measuring insulin content.
Pertussis toxin and prostaglandin E2 treatment on isolated islets.
Groups of six islets of similar size were preincubated in KRBB containing 2.8
mmol/l glucose with or without 50 ng/ml pertussis toxin (PTX) and 10 mol/l
prostaglandin E2 (PGE2) for 12 h before the study of 22.2 mmol/l glucose-
stimulated insulin secretion. The medium was collected and analyzed for
insulin concentration.
Western blotting. INS-1 cells were infected with Ad-mfat-1 and Ad-lacZ for
4 h before being switched to the medium without viral particles. After 48 h the
cells were treated with RPMI-1640 medium containing with IL-1 (5 ng/ml) or
TNF- (10 ng/ml) for various lengths of time. Analysis of extra cellular–signal
related kinse 1/2 (ERK1/2) phosphorylation and IB- phosphorylation were
performed using antibodies against phosphor-ERK1/2 and phospo–IB-, fol-
lowed by control blots with antibodies against ERK1/2 and I-, respectively.
All antibodies were from Cell Signaling.
Quantitative analysis of gene expression levels in INS-1 cells. Total
RNA was prepared using TRIZOL reagent (Invitrogen, Carlsbad, CA), treated
with DNase I (Ambion, Austin, TX), and reverse transcribed with a Superscript
kit (Invitrogen). The real-time PCRs were carried out on an ABI7900 Taqman
machine with the following cycles: 50°C for 2 min, one cycle; 95°C for 10 min,
one cycle; and 95°C for 15 s and 60°C for 1 min, 40 cycles. Rat 18s rRNA was
used as the internal control for input cDNA quantity. Linearity of each assay
was determined based on a co-efﬁcient value of at least 0.99 for the standard
curve. The cDNA concentrations of all samples were within the linear range of
the standard curve. The design of double-labeled probes and the ﬂanking
primers was carried out using Primer-Express software (Applied Biosystems,
Foster City, CA). The probes for rat pancreatic duodenal homeobox-1
(PDX-1), insulin 1, glucokinase (GK), and 18s rRNA were labeled with FAM
(5) and BHQ-1 (3). The probe and primer sequences are as follows. Rat
PDX-1: probe, 5-6FAM-ATGAAATCCACCAAAGCTCACGCGTG-3; forward
primer, 5-CCGCGTTCATCTCCCTTTC-3; reverse primer, 5-CTCCTGC
CCACTGGCTTTT-3. Rat insulin 1: probe, 5-6FAM-CAGCACCTTTGTGGTC
CTCACCTGG-3; forward primer, 5-CTGCCCAGGCTTTTGTCAA-3; reverse
primer, 5-TCCCCACACACCAGGTACAGA-3. Rat GK: probe, 5-6FAM-CCGT
GTACAAGCTGCACCCGAGC-3; forward primer, 5-CATCACTGTGGGCGTG
GAT-3, reverse primer, 5-GGCGTGAAACCGCTCCTT-3. Rat 18s rRNA:
probe, 5-6FAM-TGGACCGGCGCAAGACGGAC-3; forward primer, 5-CGC
CGCTAGAGGTGAAATTC-3; reverse primer, 5-TTGGCAAATGCTTTCGC
TC-3.
Gas chromatography analysis of fatty acid compositions. Lipids extrac-
tion from tissues was performed according to the general technique of Bligh
and Dyer (12). The gas chromatograph was performed on a Perkin Elmer
Clarus 500. Identiﬁcation of components was by comparison of retention
times with those of authentic standards (Sigma).
Statistical analysis. Data are presented as the mean  SEM. All paired
comparisons were subject to a two-tailed Student t test with P 	 0.05
considered statistically signiﬁcant.
RESULTS
Although the newly generated transgenic mouse model is
similar to the one reported earlier (called “fat-1 mice”)
(13), the codons of fat-1 cDNA are further optimized for
efﬁcient translation in mammalian systems (hence re-
named “mfat-1,”) (supplemental Fig. 1). The generation of
mfat-1 mice was not only veriﬁed through genotyping but
also conﬁrmed by examining the relative content of n-6
and n-3 PUFAs in the tails as well as in isolated pancreatic
islets (Table 1). In both tissue samples of mfat-1 transgenic
mice there was a signiﬁcant increase in n-3 PUFAs (2.6-
and 3.3-fold in tails and islets, respectively), accompanied
by a prominent decrease in n-6 PUFAs (2.7- and 3.8-fold in
tails and islets, respectively), which resulted in sharply
reduced n-6–to–n-3 ratios relative to those in the wild-type
tissues (Table 1). Interestingly, the total percentage of n-3
plus n-6 PUFAs in mfat-1 transgenic tissues was modestly
reduced, which corresponded to a minor percentage in-
crease in some other fatty acid species, primarily reﬂected
in the most dominant peak of oleic acid (see legend to
Table 1). Similar observations have been made in previ-
ously reported fat-1–expressing tissues or cells (14,15).
Although the underlying reason for this observation is still
not clear, it is likely due to the increased preferential usage
of n-3 PUFAs as substrates by various enzymes in mfat-
1–expressing tissues or cells, which might have contrib-
uted to the reduced inﬂammatory states described below.
We investigated the impact of cellular production of n-3
PUFAs on insulin secretion. In response to high glucose
stimulation, the levels of insulin secretion were signiﬁ-
cantly higher in the islets isolated from the mfat-1 trans-
genic than in those from the wild type (Fig. 1A). Addition
of GLP-1 further stimulated insulin secretion in both
wild-type and transgenic islets, but the level was signiﬁ-
cantly higher in mfat-1 transgenic islets (Fig. 1A). The
enhanced insulin secretion of mfat-1 transgenic islets was
unlikely due to enlarged islet size because confocal mi-
croscopy analysis of insulin-stained pancreatic sections
did not ﬁnd signiﬁcant difference in islet sizes between the
transgenic and wild-type groups (supplemental Fig. 2).
Although the levels of insulin secretion were expressed in
absolute concentrations (nanograms of secreted insulin/
islet, Fig. 1A), these insulin secretion patterns still held up
after we expressed them in relative concentrations (se-
creted insulin as a percentage of total insulin content,
supplemental Fig. 3A). These data depict the enhanced
insulin-secreting action of the -cells that were pre-ex-
posed to a high n-3 PUFA environment (as a result of
mfat-1 expression) even long before birth. We wondered if
acute elevation of n-3 PUFAs via mFAT-1 activity in the
-cells would also enhance insulin secretion. To this end,
we used an adenoviral expression vector to introduce
n-3 PUFAs ENHANCE ISLET FUNCTIONS AND SURVIVAL
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islets originally isolated from wild-type mice and into a rat
insulinoma cell line, INS-1. Owing to mfat-1 expression,
the cellular levels of n-3 PUFAs were sharply elevated, and
the levels of n-6 PUFAs and the ratios of n-6 to n-3 were
signiﬁcantly decreased in these virally transduced cells
(Table 1). The virally induced expression of mfat-1 in the
islets and INS-1 cells caused signiﬁcant enhancement in
glucose- and GLP-1–stimulated insulin secretion (Fig. 1B
and C and supplemental Fig. 3B and C). Interestingly, even
at the baseline of 2.8 mmol/l, glucose could evoke signiﬁ-
cantly higher insulin secretion in mfat-1–expressing islets
(though not necessarily in the insulinoma INS-1 cells) than
in control islets (Fig. 1A and B). As a result, the relative
fold of stimulation did not differ between the transgenic
and wild-type islets (supplemental Fig. 3E and F), although
this does not seem to be the case for the insulinoma INS-1
cells (supplemental Fig. 3G). Such observation made us
wonder if the high glucose concentrations only ampliﬁed
an enhanced secretion mechanism in the mfat-1–express-
ing islets and prompted us to inquire if the enhancement of
insulin secretion as a result of cell production of n-3
PUFAs is beyond the scope of high glucose and GLP-1. To
this end, we tested whether certain types of amino acid–
induced insulin secretion could also be elevated in mfat-1
transgenic islets. We adopted a widely established proto-
col to evaluate this issue by applying leucine and glu-
tamine to the culture of mfat-1 transgenic islets in the
presence of low concentrations of glucose (1.1 mmol/l)
(16). Although the amino acid mixtures stimulated insulin
secretion on top of the very low secretion levels elicited by
1.1 mmol/l glucose, there was a signiﬁcant increase of
insulin secretion in the mfat-1–expressing islets above
that in the wild-type islets (Fig. 1D and supplemental Fig.
3D). In addition, the fold of stimulation of insulin secretion
by amino acids was also substantially higher in mfat-1–
expressing islets (supplemental Fig. 3H). It should be
noted that elevation of n-3 PUFAs in islets (or INS-1 cells)
via the mfat-1 gene (delivered either transgenically or
virally) did not alter total insulin content (supplemental
Fig. 3I–L). Thus, the broad positive impact on glucose–,
amino acids–, and GLP-1–induced insulin release observed
in such engineered islets was likely due to the modulation
of secretory mechanisms.
To assess the impact of cellular production of n-3
PUFAs on the viability of pancreatic islets, we incubated
the isolated islets with a mixture of TNF-, IL-1, and
IFN- at the concentrations typically applied in previously
published studies (17). Double nuclear staining was ap-
plied to the live islets using propidium iodide and Hoechst
dye for staining dead cells and all the cells, respectively.
As expected, cytokine treatment for 48 h led to a sharply
elevated level of cell death in the wild-type islets (58 vs. 9%
in the nontreated, Fig. 2A and B); however, the islets
derived from the mfat-1 transgenic mice strongly resisted
cytokine-induced cell death (13 vs. 8% in the nontreated
islets, Fig. 2A and B).
Introduction of mfat-1 cDNA into wild-type islets or
cultured -cells using an adenoviral vector also provided
strong protection against cytokine-induced cell death.
After infected with the adenovirus carrying mfat-1 cDNA
in vitro, the INS-1 cells or pancreatic islets originally
derived from the wild-type mice displayed signiﬁcantly
reduced dead cells after cytokine challenge (Fig. 2C and
D), which was in sharp contrast to the high death rates
observed in the control islets or INS-1 cells infected with
the lacZ-carrying adenovirus (Fig. 2C and D).
The strong resistance to cytokine-induced cell death led
us to investigate the ability of cytokines to signal in
mfat-1–expressing -cells. To this end, we infected INS-1
cells with adenovirus carrying either mfat-1 or lacZ genes
and then evaluated the activation of ERK1/2 and NF-B,
two canonical pathways for IL-1 and TNF-, respectively
(18–20). Although, as expected, IL-1 signiﬁcantly stimu-
lated the activity of ERK1/2 in the lacZ-expressing INS-1
cells, it failed to do so in the mfat-1–expressing cells (Fig.
3A and B). Shortly after treatment (within 5 min), TNF-
evoked a robust and temporally dependent phosphoryla-
tion of IB-, a critical early step for the activation of
NF-B signaling pathway, in the lacZ-expressing INS-1
TABLE 1
Analysis of n-6 and n-3 PUFA composition
Total n-6 Total n-3 n-6/n-3 ratio
Mouse tissues (%)
Tails
Wild type 23.71  0.32 5.21  0.21 4.76  0.23
mfat-1 8.90  1.79* 13.72  0.87* 0.66  0.17*
Islets
Wild type 32.39  0.05 6.36  0.02 5.10  0.01
mfat-1 8.37  0.05* 21.16  0.01* 0.39  0.01*
Virally infected (%)
INS-1
Adenovirus carrying lac-Z cDNA 13.13  0.83 2.29  0.49 5.54  1.78
Adenovirus carrying mfat-1 cDNA 4.12  0.65* 8.26  0.27* 0.50  0.09*
Wild-type
Adenovirus carrying lac-Z cDNA 28.42  0.30 7.73  0.11 3.68  0.01
Adenovirus carrying mfat-1 cDNA 18.85  0.12* 15.48  0.07* 1.22  0.01*
Data are means  SD. The tissues (50 mg of tail samples or 200 islets) were collected from the mfat-1 transgenic or wild-type control mice.
Fatty acid analysis was also performed on the INS-1 or the wild-type islets infected with adenoviral vectors carrying either mfat-1 or lacZ
cDNA. The compositions of n-6 or n-3 PUFAs were expressed using relative percentages, i.e., the distribution areas of n-3 or n-6 PUFA peaks
divided by the total peak areas of all detectable saturated and unsaturated free fatty acids (from the same sample) resolved from the gas
chromatography column. In the transgenic tissues, the modest drop in relative percentages of n-3 plus n-6 PUFAs corresponded to a minor
percentage increase in some other detectable fatty acid species. However, the increase was primarily reﬂected in the most dominant peak
of oleic acids (tails, 26.9% 
wt vs. 33.0% 
mfat-1; islets, 17.6% 
wt vs. 22.8% 
mfat-1). The speciﬁcity of mfat-1 enzymatic activity primarily
caused the changes of n-6 and n-3 PUFAs. n  4. *P 	 0.001 when mfat-1 group compared with corresponding control (wt or lacZ) group.
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IB- induced by TNF- was sharply attenuated and even
delayed in the mfat-1–expressing cells (Fig. 3C and D).
Such differential cytokine signaling pattern is very likely to
have contributed to strong resistance of mfat-1–express-
ing -cells to cytokine-induced cell death.
To gain further mechanistic understanding of the afore-
mentioned phenotypes related to insulin secretion, we
focused on the roles of inﬂammation modulation. Eleva-
tion of n-3 PUFAs is known to suppress the production of
PGE2 (21,22), a negative regulator of glucose-stimulated
insulin secretion (23,24). We found that PGE2 concentra-
tion was signiﬁcantly reduced in the medium incubated
with the mfat-1–expressing INS-1 cells relative to that
incubated with the lacZ-expressing control cells (Fig. 4A).
Similarly, the medium culturing the mfat-1 transgenic
islets contained less PGE2 than the one culturing the
wild-type islets (Fig. 4B). As expected, addition of arachi-
donic acid (AA, an n-6 PUFA), a substrate of cycloxygen-
ase-2 (COX-2) for PGE2 synthesis, to the incubation
medium increased PGE2 secretion from INS-1 cells; how-
ever, such an increase was signiﬁcantly attenuated in
mfat-1–expressing INS-1 cells (Fig. 4A). Preincubation
with PGE2 (10 mol/l) for 12 h attenuated glucose-stimu-
lated insulin secretion in the mfat-1 transgenic and wild-
type islets (Fig. 4C). Importantly, pretreatment with PGE2
completely neutralized the mfat-1–caused enhancement
in insulin secretion (Fig. 4C, no statistical signiﬁcance
when comparing mfat-1
PGE2 vs. wild-type without
PGE2), suggesting that the reduction of PGE2 synthesis
plays a critical role in n-3 PUFA–regulated insulin secre-
tion. Inhibitory regulatory G-protein (Gi) has been thought
as a major signaling component in mediating the actions of
PGE2 (25,26). Preincubation of pancreatic islets with per-
FIG. 1. Insulin secretion in response to glucose, amino acids, and GLP-1 stimulation in transgenic or adenoviral-driven expression of mfat-1 islets
or INS-1 cells. A: Islets isolated from the transgenic (mfat-1) or wild-type (wt) mice were incubated with different concentrations of glucose in
the presence or absence of GLP-1 (10 nmol/l) for 30 min. The medium was harvested for the measurement of insulin concentration. B and C:
Isolated islets from wild-type mice (B) or INS-1 cells (C) were preinfected with adenovirus carrying mfat-1 or lacZ genes for 24 h before the study
of insulin secretion, as outlined in A. D: Islets isolated from wild-type and mfat-1 transgenic mice were incubated with 1.1 mmol/l glucose in the
presence or absence of 10 mmol/l leucine (Leu) and 10 mmol/l glutamine (Glu) for 60 min before the medium was collected for measurement of
secreted insulin. In A–D, the levels of secreted insulin (ng/islet) in each panel were the means  SEM of three independent experiments with each
condition carried out in ﬁve or six replicates and 10–20 islets in each replicate.
#P < 0.01, *P < 0.05 when compared with the control group.
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(27,28), partially rescued insulin secretion in the wild-type
islets and completely neutralized the inhibitory effect of
PGE2 on insulin secretion (Fig. 4C), suggesting that the
aforementioned action of PGE2 was mediated at least in
part through Gi. Finally, in analyzing gene expression, we
further found that elevation of n-3 PUFAs through mFAT-1
activity in the -cells could lead to changes in the expres-
sion of certain genes that are critical to the functions and
viability of -cells. For example, the mRNA levels of
PDX-1, GK, and insulin (insulin1) were signiﬁcantly in-
creased in the INS-1 cells infected with adenoviruses
carrying mfat-1 cDNA relative to the lacZ-expressing
control cells (Fig. 5).
DISCUSSION
In this study, we have shown that cellular increase of n-3
PUFAs and reduction of n-6 PUFAs through transgenic
expression of mfat-1 enhances glucose–, amino acid–, and
GLP-1–stimulated insulin secretion in isolated pancreatic
islets and renders the islets strongly resistant to cytokine-
induced cell death. Acute and stable elevation of n-3
PUFAs through adenoviral transduction of mfat-1 gene in
isolated islets and in INS-1 cells was able to recapitulate
the observations in the mfat-1 transgenic islets.
Although the underlying mechanisms remain to be sys-
tematically investigated, initial studies described here of-
fer some mechanistic insights into how mfat-1 expression
FIG. 2. Cytokine-induced apoptosis of cultured islets or
INS-1 cells. A and B: Isolated islets from transgenic or wild
type were challenged with the cytokine mix for 48 h before
ﬂuorescent confocal imaging. C and D: Islets derived from
wild-type mice (C) or INS-1 cells (D) were infected with
adenovirus carrying either mfat-1 or lacZ gene for 24 h
before being challenged with the cytokine mix for 48 h. The
live islets or cells were incubated with propidium iodide
and Hoechst dye before imaging analysis. The images were
collected under either a confocal (for islets) or regular (for
INS-1) ﬂuoresecent microscope. The rates of cell death
were calculated based on at least four randomly selected
sections or areas of the images.
#P < 0.01 when compared
with the corresponding control group. (A high-quality dig-
ital representation of this ﬁgure is available in the online
issue.)
D. WEI AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, FEBRUARY 2010 475(and the subsequent changes in PUFA lipid species)
impact insulin secretion as well as the survival of pancre-
atic -cells. For example, PGE2 has been well demon-
strated as a negative regulator of insulin secretion (23,24).
The reduction of PGE2 synthesis in the mfat-1–expressing
cells or islets was the result of decreased availability of
AA, an n-6 PUFA, to COX-2 enzyme, as mFAT-1 activity
converted AA to EPA (eicosapentaenoic acid). Consistent
with this concept, AA-induced synthesis of PGE2 was also
attenuated in mfat-1–expressing cells (Fig. 3A). Though
not necessarily the only mechanism, the regulation of
PGE2 largely contributed to the elevation of insulin secre-
tion in mfat-1–expressing islets, since addition of 10
mol/l PGE2 to the islet culture almost completely elimi-
nated the increased portion of insulin secretion (relative to
that in the wild-type islets without PGE2 treatment) (Fig.
3C). In strengthening this argument, we have revealed that
the negative impact of PGE2 on insulin secretion is medi-
ated at least in part by Gi, as pertussis toxin was able to
neutralize the action of PGE2 while co-incubated with
mfat-1 transgenic and wild-type islets. Thus, the reduction
of PGE2 secretion from the mfat-1–expressing islets and
-cells is critical for the enhanced insulin secretion, sug-
gesting that the control of inﬂammation through reduction
of n-6 PUFAs can have a beneﬁcial effect on -cell
functions.
The strong resistance to cytokine-caused destruction in
mfat-1–expressing islets and INS-1 cells was also reﬂected
at the level of cytokine signaling. Speciﬁcally, we have
shown that cytokine-induced activation of ERK1/2 and
NF-B pathways was signiﬁcantly suppressed, both of
which were critical for cytokines’ actions. We should
emphasize that the attenuation of TNF-–activated NF-B
signaling is not necessarily conﬁned to the pancreatic
-cells only. Our recent studies have found similar obser-
vations in fat-1 transgenic hepatocytes (J.L. and A.Z.,
unpublished observations). Thus, the control of cytokine
signaling appears to be a common theme that has broad
physiological implications. Although it is predicted to
enhance insulin signaling and sensitivity in the liver tissue,
the reduction of TNF-–activated NF-B signaling leads to
protection from cytokine-inﬂicted islet destruction. Fi-
nally, from the perspective of gene expression, mfat-1–
induced increase in PDX-1, glucokinase, and insulin 1
expression may have also played important roles in im-
proved insulin secretion and -cell survival.
Modern diets contain excessive n-6 PUFAs but very low
levels of n-3 PUFAs, which results in an unhealthy n-6–
to–n-3 ratio of 20:1 instead of the ideal 1:1 (29). Since the
eicosanoid products derived from n-6 PUFAs are more
potent mediators of inﬂammation than the similar prod-
ucts derived from n-3 PUFAs, an imbalanced n-6–to–n-3
ratio in favor of n-6 PUFAs will be highly proinﬂammatory,
which is believed to have contributed to the pathogenesis
of such modern diseases as autoimmune disorders and
diabetes (1,30). The production of n-3 PUFAs in the -cells
and islets via mFAT-1 activity is achieved by using n-6
PUFAs as the substrates, thus bringing down the ratios of
n-6 to n-3 as well as the inﬂammatory state. Thus, although
the increase of n-3 PUFAs is critical, the decrease of n-6
PUFAs may be just as important in determining the
phenotypes of mfat-1–expressing islets. In keeping with
this concept, we have already shown that the reduction of
PGE2 secretion from the mfat-1–expressing islets and
FIG. 3. Activation of ERK1/2 and NF-B in INS-1 cells infected with Ad-mfat-1 or Ad-lacZ. INS-1 cells were infected with Ad-mfat-1 or Ad-LacZ
for 4 h. Approximately 48 h later, the cells were exposed to IL-1 (5 ng/ml) (A and B) or TNF- (10 ng/ml) (C and D) for the indicated time. The
cells were then extracted for protein for Western blot assays of ERK1/2 and IB- phosphorylation. The level of phosphorylation was quantiﬁed
with Image J software.
#P < 0.01, *P < 0.05 when compared with the corresponding control group.
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gesting that the control of inﬂammation through reduction
of n-6 PUFAs is a main theme in the regulation of -cell
functions by n-3 PUFAs.
Recent clinical studies have established that daily com-
pensation of n-3 PUFAs starting at 1 year of age can have
clear beneﬁts against the development of type 1 diabetes
and islet autoimmunity (6). Consistent with these clinical
observations, studies in rodents have shown that adminis-
tration of n-3 PUFAs could restore palmitate- or linoleic
acid–impaired insulin secretion (8,9). Although we cannot
fully equate our transgenic approach to the dietary means
of gaining n-3 PUFAs, both methods provide the same
types of n-3 PUFAs to the whole body. The results
presented here suggest that elevation of cellular n-3
PUFAs has a direct beneﬁcial impact on the survival of
pancreatic -cells from inﬂammation attack and that they
may explain mechanistically why increased intake of n-3
PUFAs in early childhood can help reduce the incidence of
type 1 diabetes. Our data may also add n-3 PUFAs to the
growing list of factors that can help improve the functions
and viability of -cells. Thus, it warrants further investiga-
tion whether mfat-1 expression in disease models such as
nonobese diabetic (NOD) mice can mitigate the develop-
ment of type 1 diabetes.
From a therapeutic perspective, the phenotypes of the
islets infected with mfat-1–containing adenovirus bear
strong clinical relevance. Engineered islets with enhanced
insulin secretion and viability are always sought to over-
come inﬂammatory destruction and the scarcity of avail-
able islets (31,32). In this context, the mfat-1–expressing
islets should be urgently tested in transplantation settings
and may represent an additional tool for the treatment of
type 1 diabetes.
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